European Association for the Study of the Liver (EASL) Congress 2023

Age, tumour size predict post-TACE complications in HCC patients

Stephen Padilla, 20230721120000

In patients with hepatocellular carcinoma (HCC), most complications following transarterial chemoembolization (TACE) involve minor postembolization syndrome, reveals a study presented at EASL 2023. The incidence of major complications is high at 25 percent, with a 1.8-percent death rate.

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

Jairia Dela Cruz, 20230720140000

Among patients with treatment-naïve autoimmune hepatitis, more of those who receive mycophenolate mofetil achieve remission than those who receive azathioprine, as shown in the results of the CAMARO trial.

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

Stephen Padilla, 20230720120000

The addition of simvastatin to a nonselective beta blocker results in better survival among cirrhotic patients with variceal bleeding, reports a study presented at EASL 2023.

Resmetirom delivers improved outcomes for NASH patients with fibrosis

Jairia Dela Cruz, 20230719140000

The THR-β selective agonist resmetirom helps resolve nonalcoholic steatohepatitis (NASH) and reduce fibrosis, with the drug being safe and well-tolerated, according to data from the large phase III pivotal MAESTRO-NASH trial presented at EASL 2023.

Anti-obesity therapies go beyond weight loss

Audrey Abella, 20230719100000

Weight loss strategies do not only provide therapeutic alternatives for obesity but may also hold promise in the management of type 2 diabetes (T2D) and NAFLD*.

Phase III data support long-term efficacy of TAF against HBV

Audrey Abella, 20230718100000

Two phase III studies presented at EASL 2023 reflected the long-term efficacy of tenofovir alafenamide (TAF) for individuals with HBeAg*-positive and HBeAg-negative chronic hepatitis B virus (HBV).